

23 March 2020


ASX Announcement

Notification of Expiry of Unlisted Options

23 March 2020 – Race Oncology Limited (ASX: RAC) confirms the lapse of the 750,000 unlisted options exercisable at \$0.32 and expiring on 16 May 2023 due to the termination of a consultancy agreement.

The total number of unlisted options on issue following the expiry is as follows:

Expiry Date	Exercise Price	Number
1 July 2021	\$0.25	9,000,000
1 August 2021	\$0.256	135,000
31 August 2021	\$0.099	10,854,542
25 November 2021	\$0.25	3,000,000
27 November 2021	\$0.23	2,000,000
12 March 2022	\$0.45	1,500,000
1 April 2022	\$0.25	1,500,000
8 May 2022	\$0.25	100,000
25 November 2022	\$0.19	2,500,000
16 May 2023	\$0.32	750,000
1 October 2023	\$0.12	420,000
21 January 2024	\$0.12	420,000
17 February 2024	\$0.49	2,400,000
12 March 2024	\$0.135	100,000
31 May 2024	\$0.085	840,000
5 December 2024	\$0.18	840,000
23 January 2025	\$0.275	2,400,000
		38,759,542



Peter Webse
Company Secretary

Release authorised by:
Peter Molloy, Managing Director
plmolloy@raceoncology.com

Media contact:
Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

About Race Oncology (RAC: ASX)

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drugs in the cancer field that have been overlooked by big pharma. The company's first drug is Bisantrene, a chemotherapy agent that was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned. Bisantrene has compelling clinical data in acute myeloid leukaemia (AML) as well as other cancers including breast and ovarian. Race is seeking to gain US FDA approval for Bisantrene. Bisantrene is the subject of three recently granted US patents owned by Race and has been awarded US Orphan Drug designation and a 'Rare Paediatric Disease' (RPD) designation that entitles Race to a valuable Priority Review Voucher (PRV) upon approval.